Tag: preclinical
-
Virtual Reality Harnessed to View Inside Blood Vessels
A medical team demonstrated the feasibility of virtual reality to visualize and guide a catheter inside blood vessels through a three-dimensional human model.
-
Biotechs Join Forces for Off-the-Shelf Stem Cells
Two biotechnology enterprises working in genome editing and regenerative medicine are sharing their technologies to develop off-the-shelf cell therapies.
-
Respiratory Vaccine Maker Raises $3.4M in Seed Funds
A company developing vaccines that protect against respiratory diseases in vulnerable populations is raising new seed funds to advance its lead product into clinical trials.
-
Celgene Adopting A.I. Drug Discovery Technology
Drug maker Celgene is gaining access to an artificial intelligence platform developed by Exscientia Ltd, to find treatment candidates for cancer and autoimmune disorders.
-
NIH Funds Natural Hearing Restoration Technology
An international group of universities and companies is designing a next-generation device to restore more natural hearing to people suffering from hearing loss.
-
NIH Funding Nanodrugs to Prevent Opioid Addiction
A drug that invokes the immune system to block addictive effects of opioid pain drugs and heroin is in early development at Washington University in St. Louis.
-
Univ. Developing Implanted Islet Cell Bags for Diabetes
Implantable collections of insulin-producing islet cells resembling tea bags, for people with type 1 diabetes, are being developed by researchers at University of Arizona.
-
Gene Editing Deactivates Cause of T-Cell Side Effects
A biotechnology company developing engineered T-cells as treatments for cancer, used gene editing to deactivate a likely cause of serious adverse effects from its therapies.
-
FDA Drafts Brain-Computer Device Regulatory Guidance
Food and Drug Administration is releasing for comment regulatory guidance for its review of implanted medical devices that connect human brains to computer systems.
-
Start-Up Raises $10.5M for Precision Immunotherapies
A new biotechnology enterprise developing personalized treatments that harness the immune system to treat cancer is raising $10.5 million in its first venture funding round.